Trial · NCT03364335

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

NCT03364335, Phase 2, Completed, NuSirt Biopharma; results first posted 2018-11-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity. Trials, record NCT03364335. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03364335

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity
NCT number: NCT03364335
Status: Completed
Phases: Phase 2
Enrollment: 267 participants, actual
Lead sponsor: NuSirt Biopharma
Conditions: Obesity
Interventions: Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg, Leu Met Sil 4.0mg, Placebo
First posted: 2017-12-06
Last updated: 2019-08-21
Results first posted: 2018-11-27

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage Body Weight Change	Baseline to Day 168	The percentage body weight change from baseline to Day 168 was evaluated.
Secondary	Change in Absolute Body Weight	Baseline to Day 168	The change in absolute body weight from baseline to day 168 was evaluated.
Secondary	Change in Percentage of Patients With ≥5% Body Weight Loss	Baseline to Day 168	The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.
Secondary	Change in Waist Circumference	Baseline to Day 168	The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.
Secondary	Change in Total Cholesterol	Baseline to Day 168	Changes in total cholesterol was examined by standard blood chemistry.
Secondary	Change in HDL Cholesterol	Baseline, Day 168	Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.
Secondary	Change in LDL Cholesterol	Baseline, 168 days	Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.
Secondary	Change in Triglycerides	Baseline, Day 168	The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.
Secondary	Change in Plasma Glucose	Baseline to Day 168	Change in plasma glucose was examined through standard fasting blood chemistry.
Secondary	Change in Hemoglobin A1c (HbA1c)	Baseline, Day 168	Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.

1 to 10 of 13Source ClinicalTrials.gov

See all 13 registered outcomes

Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage Body Weight Change	Baseline to Day 168	ANCOVA Analysis for Primary Endpoint - Percent Change in Body Weight from Baseline to Day 168 in per protocol population.	percentage	MEAN
SECONDARY	Change in Absolute Body Weight	Baseline to Day 168	ANCOVA Analysis for Secondary Endpoint - Change in Absolute Body Weight from Baseline to day 168 (Per-Protocol Population).	kg	MEAN
SECONDARY	Change in Percentage of Patients With ≥5% Body Weight Loss	Baseline to Day 168	Analysis for Secondary Endpoint - Percentage of Subjects with ≥5% Relative Percentage Reduction from Baseline to day 168 in Body Weight by Treatment (Per-Protocol Population).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change in Waist Circumference	Baseline to Day 168	ANCOVA Analysis for Secondary Endpoint - Change in Waist Circumference from Baseline (Per-Protocol Population).	cm	MEAN
SECONDARY	Change in Total Cholesterol	Baseline to Day 168	ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).	mg/dL	MEAN
SECONDARY	Change in HDL Cholesterol	Baseline, Day 168	ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).	mg/dL	MEAN
SECONDARY	Change in LDL Cholesterol	Baseline, 168 days	ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).	mg/dL	MEAN
SECONDARY	Change in Triglycerides	Baseline, Day 168	ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).	mg/dL	MEAN
SECONDARY	Change in Plasma Glucose	Baseline to Day 168	ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).	mg/dL	MEAN
SECONDARY	Change in Hemoglobin A1c (HbA1c)	Baseline, Day 168	ANCOVA Analysis for Secondary Endpoint - Change in HbA1c from Baseline to day 168 (Per-Protocol Population).	percentage of glycosylated hemoglobin	MEAN

1 to 10 of 13Source ClinicalTrials.gov

See all 13 outcomes

Results by group65

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Percentage Body Weight Change	Placebo	1.121	Standard Deviation 3.6241	percentage
Percentage Body Weight Change	Leu Sil 1.0mg	0.674	Standard Deviation 3.2286	percentage
Percentage Body Weight Change	Leu Sil 4.0mg	-0.489	Standard Deviation 3.9041	percentage
Percentage Body Weight Change	Leu Met Sil 1.0mg	-0.929	Standard Deviation 4.5533	percentage
Percentage Body Weight Change	Leu Met Sil 4.0mg	-0.552	Standard Deviation 2.5924	percentage
Change in Absolute Body Weight	Placebo	1.126	Standard Deviation 3.5903	kg
Change in Absolute Body Weight	Leu Sil 1.0mg	0.678	Standard Deviation 3.2502	kg
Change in Absolute Body Weight	Leu Sil 4.0mg	-0.460	Standard Deviation 4.0352	kg
Change in Absolute Body Weight	Leu Met Sil 1.0mg	-0.870	Standard Deviation 4.5445	kg
Change in Absolute Body Weight	Leu Met Sil 4.0mg	-0.461	Standard Deviation 2.7583	kg

1 to 10 of 65Source ClinicalTrials.gov

See all 65 results by group

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	52
Overall Study	STARTED	Leu Sil 1.0mg	51
Overall Study	STARTED	Leu Sil 4.0mg	53
Overall Study	STARTED	Leu Met Sil 1.0mg	50
Overall Study	STARTED	Leu Met Sil 4.0mg	52
Overall Study	COMPLETED	Placebo	42
Overall Study	COMPLETED	Leu Sil 1.0mg	40
Overall Study	COMPLETED	Leu Sil 4.0mg	42
Overall Study	COMPLETED	Leu Met Sil 1.0mg	37
Overall Study	COMPLETED	Leu Met Sil 4.0mg	41

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events100

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal Pain	Gastrointestinal disorders	Placebo	1	52	1
other	Abdominal Pain	Gastrointestinal disorders	Leu Sil 1.0mg	0	51	0
other	Abdominal Pain	Gastrointestinal disorders	Leu Sil 4.0mg	1	53	1
other	Abdominal Pain	Gastrointestinal disorders	Leu Met Sil 1.0mg	3	50	3
other	Abdominal Pain	Gastrointestinal disorders	Leu Met Sil 4.0mg	1	52	1
other	Arthralgia	Musculoskeletal and connective tissue disorders	Placebo	0	52	0
other	Arthralgia	Musculoskeletal and connective tissue disorders	Leu Sil 1.0mg	4	51	4
other	Arthralgia	Musculoskeletal and connective tissue disorders	Leu Sil 4.0mg	0	53	0
other	Arthralgia	Musculoskeletal and connective tissue disorders	Leu Met Sil 1.0mg	0	50	0
other	Arthralgia	Musculoskeletal and connective tissue disorders	Leu Met Sil 4.0mg	0	52	0

1 to 10 of 100Source ClinicalTrials.gov

See all 100 adverse events

Adverse event totals15

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	52
Total, all-cause mortality	Leu Sil 1.0mg	0	51
Total, all-cause mortality	Leu Sil 4.0mg	0	53
Total, all-cause mortality	Leu Met Sil 1.0mg	0	50
Total, all-cause mortality	Leu Met Sil 4.0mg	0	52
Total, other adverse events	Placebo	14	52
Total, other adverse events	Leu Sil 1.0mg	19	51
Total, other adverse events	Leu Sil 4.0mg	12	53
Total, other adverse events	Leu Met Sil 1.0mg	21	50
Total, other adverse events	Leu Met Sil 4.0mg	19	52

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03364335

GET https://conductscience.org/api/trials/v1/NCT03364335/results?page=2

API reference For AI assistants